161 related articles for article (PubMed ID: 22918471)
1. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
Wieking BG; Vermeer DW; Spanos WC; Lee KM; Vermeer P; Lee WT; Xu Y; Gabitzsch ES; Balcaitis S; Balint JP; Jones FR; Lee JH
Cancer Gene Ther; 2012 Oct; 19(10):667-74. PubMed ID: 22918471
[TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus 16 E6 and E7 Synergistically Repress Innate Immune Gene Transcription.
James CD; Fontan CT; Otoa R; Das D; Prabhakar AT; Wang X; Bristol ML; Morgan IM
mSphere; 2020 Jan; 5(1):. PubMed ID: 31915229
[TBL] [Abstract][Full Text] [Related]
3. Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.
Pellom ST; Smalley Rumfield C; Morillon YM; Roller N; Poppe LK; Brough DE; Sabzevari H; Schlom J; Jochems C
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651712
[TBL] [Abstract][Full Text] [Related]
4. Transforming Properties of Beta-3 Human Papillomavirus E6 and E7 Proteins.
Minoni L; Romero-Medina MC; Venuti A; Sirand C; Robitaille A; Altamura G; Le Calvez-Kelm F; Viarisio D; Zanier K; Müller M; Accardi R; Tommasino M
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669468
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.
Zhao L; Liu B; Ren J; Feng J; Pang Z; Gao J; Zhang H; Tan W; Tian H; Ruan L
Virol J; 2011 Jun; 8():302. PubMed ID: 21672263
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
7. NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice.
Sadr-Momtaz S; Aftabi M; Behboudi E; Naderi M; Hashemzadeh-Omran A; Moradi A
BMC Res Notes; 2023 Aug; 16(1):164. PubMed ID: 37550734
[TBL] [Abstract][Full Text] [Related]
8. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model.
Strati K; Pitot HC; Lambert PF
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14152-7. PubMed ID: 16959885
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of MmuPV1 E6 and E7 and Implications for Human Disease.
Romero-Masters JC; Lambert PF; Munger K
Viruses; 2022 Sep; 14(10):. PubMed ID: 36298698
[TBL] [Abstract][Full Text] [Related]
10. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.
Al-Taei S; Banner R; Powell N; Evans M; Palaniappan N; Tabi Z; Man S
Cancer Immunol Immunother; 2013 Dec; 62(12):1821-30. PubMed ID: 24146146
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccines for high-risk HPV-associated diseases.
Chabeda A; Yanez RJR; Lamprecht R; Meyers AE; Rybicki EP; Hitzeroth II
Papillomavirus Res; 2018 Jun; 5():46-58. PubMed ID: 29277575
[TBL] [Abstract][Full Text] [Related]
12. CREB1 activation promotes human papillomavirus oncogene expression and cervical cancer cell transformation.
Li Y; Patterson MR; Morgan EL; Wasson CW; Ryder EL; Barba-Moreno D; Scarth JA; Wang M; Macdonald A
J Med Virol; 2023 Aug; 95(8):e29025. PubMed ID: 37565725
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analysis of immune characteristics in tumors with alternative carcinogenesis pathways induced by human papillomaviruses.
Smahel M; Nunvar J
Virol J; 2023 Dec; 20(1):287. PubMed ID: 38049810
[TBL] [Abstract][Full Text] [Related]
14. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization.
Lee S; Yoon H; Hong SH; Kwon SP; Hong JJ; Kwak HW; Park HJ; Yoo S; Bae SH; Park HJ; Lee J; Bang YJ; Lee YS; Kim JY; Yoon S; Roh G; Cho Y; Kim Y; Kim D; Park SI; Kim DH; Lee S; Oh A; Ha D; Lee SY; Park M; Hwang EH; Bae G; Jeon E; Park SH; Choi WS; Oh HR; Kim IW; Youn H; Keum G; Bang EK; Rhee JH; Lee SE; Nam JH
J Med Virol; 2023 Dec; 95(12):e29309. PubMed ID: 38100632
[TBL] [Abstract][Full Text] [Related]
15. The biology of beta human papillomaviruses.
Tommasino M
Virus Res; 2017 Mar; 231():128-138. PubMed ID: 27856220
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the PDZ motif of HPV16 E6 preventing immortalization and anchorage-independent growth in human tonsil epithelial cells.
Spanos WC; Geiger J; Anderson ME; Harris GF; Bossler AD; Smith RB; Klingelhutz AJ; Lee JH
Head Neck; 2008 Feb; 30(2):139-47. PubMed ID: 17657785
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus E6 and E7 oncoproteins affect the expression of cancer-related microRNAs: additional evidence in HPV-induced tumorigenesis.
Chiantore MV; Mangino G; Iuliano M; Zangrillo MS; De Lillis I; Vaccari G; Accardi R; Tommasino M; Columba Cabezas S; Federico M; Fiorucci G; Romeo G
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1751-63. PubMed ID: 27300513
[TBL] [Abstract][Full Text] [Related]
18. Modulation of therapeutic sensitivity by human papillomavirus.
Swick AD; Chatterjee A; De Costa AM; Kimple RJ
Radiother Oncol; 2015 Sep; 116(3):342-5. PubMed ID: 26364887
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer.
Jiang Z; Albanese J; Kesterson J; Warrick J; Karabakhtsian R; Dadachova E; Phaëton R
Transl Oncol; 2019 Oct; 12(10):1289-1295. PubMed ID: 31325765
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies.
Wang J; Ma L; Chen Y; Zhou R; Wang Q; Zhang T; Yi D; Liu Q; Zhang Y; Zhang W; Dong Y; Cen S
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38514186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
